| 251 |
18805633 | The N-terminal domain of EBNA1 acts as a suppressor of the HER2/neu oncogene. | 2009 Jan 18 |
2 |
| 252 |
19042015 | The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. | 2009 Feb |
5 |
| 253 |
19118059 | Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. | 2009 Jan 1 |
1 |
| 254 |
19228734 | Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. | 2009 Feb 15 |
7 |
| 255 |
19258951 | Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. | 2009 Jan |
4 |
| 256 |
19295274 | [Preoperative therapy using trastuzumab and weekly paclitaxel in a stage IIIB inoperable locally advanced HER2- positive breast cancer with complete pathologic response]. | 2009 Mar |
2 |
| 257 |
19331197 | Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer. | 2009 Feb |
1 |
| 258 |
19372587 | ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. | 2009 Apr |
5 |
| 259 |
19632322 | Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. | 2009 Oct 8 |
4 |
| 260 |
19691751 | Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy. | 2009 Aug |
2 |
| 261 |
19720916 | Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. | 2009 Oct 1 |
1 |
| 262 |
19755824 | [Combination treatment with trastuzumab and Paclitaxel as primary therapy for advanced breast cancer]. | 2009 Sep |
1 |
| 263 |
19794992 | Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy. | 2009 Oct |
3 |
| 264 |
19858400 | Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. | 2009 Nov 20 |
1 |
| 265 |
19887543 | A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. | 2009 Nov |
3 |
| 266 |
19918289 | Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature. | 2009 Sep 15 |
1 |
| 267 |
20062660 | Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report. | 2009 Dec 4 |
1 |
| 268 |
17468948 | HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. | 2008 Mar |
2 |
| 269 |
17953985 | Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. | 2008 Feb |
1 |
| 270 |
18364725 | HER2 positivity predicts a benefit from paclitaxel treatment after adjuvant chemotherapy. | 2008 May |
1 |
| 271 |
18365200 | Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. | 2008 Nov |
1 |
| 272 |
18375893 | Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. | 2008 Apr 1 |
2 |
| 273 |
18685414 | Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond. | 2008 Sep |
2 |
| 274 |
18766004 | Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. | 2008 Oct |
4 |
| 275 |
18955454 | Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. | 2008 Dec 1 |
2 |
| 276 |
18985033 | Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. | 2008 Dec 2 |
1 |
| 277 |
19106581 | [A long-term survival case of metastatic breast cancer treated with trastuzumab and paclitaxel]. | 2008 Nov |
1 |
| 278 |
16850247 | Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. | 2007 Mar |
1 |
| 279 |
17200359 | Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. | 2007 Jan 1 |
2 |
| 280 |
17220672 | [Preoperative therapy with trastuzumab and paclitaxel in a stage IV advanced breast cancer with complete pathologic response]. | 2007 Jan |
1 |
| 281 |
17343796 | [Apoptotic effect of the combined treatment of engineered antibody with paclitaxel on BT474 cells]. | 2007 Mar |
6 |
| 282 |
17465239 | Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer. | 2007 Mar-Apr |
2 |
| 283 |
17586082 | Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. | 2007 Jul 31 |
1 |
| 284 |
17647266 | Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. | 2007 Sep 15 |
1 |
| 285 |
17660958 | The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. | 2007 Feb |
3 |
| 286 |
17828616 | Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. | 2007 Dec |
3 |
| 287 |
17879382 | Design and synthesis of paclitaxel conjugated with an ErbB2-recognizing peptide, EC-1. | 2007 Nov |
4 |
| 288 |
17928597 | HER2 and response to paclitaxel in node-positive breast cancer. | 2007 Oct 11 |
4 |
| 289 |
17987122 | HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. | 2007 Nov 7 |
1 |
| 290 |
18022396 | Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. | 2007 Dec 22 |
1 |
| 291 |
18038883 | When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients? | 2007 Sep-Oct |
1 |
| 292 |
18083698 | Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. | 2007 Dec |
1 |
| 293 |
18086299 | CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. | 2007 |
1 |
| 294 |
16467098 | Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. | 2006 Feb 1 |
1 |
| 295 |
16580691 | 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells. | 2006 May 15 |
4 |
| 296 |
16764747 | Subacute cerebellar degeneration as paraneoplastic syndrome: initial symptom of breast cancer with HER2 overexpression. | 2006 Apr |
1 |
| 297 |
16782917 | Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. | 2006 Jun 20 |
1 |
| 298 |
16847284 | Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. | 2006 Aug 10 |
1 |
| 299 |
16969027 | [A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy]. | 2006 Sep |
3 |
| 300 |
17146157 | Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience. | 2006 |
1 |